Antifungal Prophylaxis after CAR T-cell Therapy: Incidence of Invasive Fungal Infections and Effects on the Microbiome.

Key Points

• Invasive fungal infections increase in patients undergoing CAR T-cell therapy, signaling a need for effective prevention strategies.
• Among 120 treated individuals, 22% experienced fungal infections within three months post-therapy, majorly affecting recovery.
• Assessment focused on antifungal prophylaxis and its impact on the microbiome in patients with CAR T-cell therapy.
• Identifies microbiome changes linked to antibiotic use; suggests potential roles in infection risk, meriting further investigation.